Clinical Trial Update: A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial GS-9219 in chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and multiple myeloma (Phase 1/2) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• GS-9219

Snippet

Sponsor: Gilead Sciences | Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED